Abstract: A method comprises obtaining a plurality of variable size chunks of data, calculating a first hash for each variable size chunk of data, determining a length representation for each variable size chunk of data, determining a second hash of a subset of each variable size chunk of data, and forming a signature of each variable size chunk of data that is comprised of the first hash, the length representation and the second hash.

Abstract: A system and method obtain a set of data and identify successive subsets of data within the set of data. A boundary identifying hash is calculated on a subset of data and compared with a boundary indicating value. If the calculated boundary identifying hash matches the boundary indicating value, a natural boundary is identified in the set of data.

Abstract: A system and method include selecting a file for potential backing up. A metadata signature is calculated on the selected file. The metadata signature of the selected file is compared to a metadata signature of a corresponding file already backed up. The file is only backed up the file if the signatures do not match.

Abstract: This invention relates to the use of short interfering nucleic acid molecules (siRNA) to inhibit Nuclear Mitotic Apparatus Protein (NuMA) gene expression and their use in treatment of disease, including cancer.

Abstract: This invention relates to the use of short nucleic acid molecules that modulate Aurora-B kinase (AurkB) expression. The invention includes compounds, compositions and methods useful for the modulation of expression and activity of genes involved in the AurkB pathway. In one embodiment, the present invention provides short nucleic acid molecules, such as siRNA, which can be used in treating, preventing, or inhibiting cancer, and any other proliferative disease, trait or condition, which respond to a reduction in AurkB expression in a cell or tissue. Such short nucleic acid molecules can be used alone or in combination with other treatments or therapies, including short nucleic acid molecules that modulate expression of EGFR.

Abstract: A process for preparing sertraline hydrochloride includes reacting trans-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthaleneamine with a base in an aqueous basic organic solvent.